<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35311">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646878</url>
  </required_header>
  <id_info>
    <org_study_id>CEP310</org_study_id>
    <nct_id>NCT02646878</nct_id>
  </id_info>
  <brief_title>A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics</brief_title>
  <official_title>A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the performance of the Harmony 1 Sensor in
      subjects age 14 - 75 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center, prospective single-sample correlational design without
      controls.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Harmony 1 Sensor insertions and removals as assessed by site and subject report</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events as assessed by site and subject report</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Harmony 1 Sensor Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects wearing Harmony 1 Sensor will be assigned this group which will determine when they will be participating in the in-clinic YSI frequent sample testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Harmony 1 Sensor Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects wearing Harmony 1 Sensor will be assigned this group which will determine when they will be participating in the in-clinic YSI frequent sample testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Harmony 1 Sensors</intervention_name>
    <description>Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.</description>
    <arm_group_label>Harmony 1 Sensor Group A</arm_group_label>
    <arm_group_label>Harmony 1 Sensor Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 14 - 75 years of age at time of screening

          2. A clinical diagnosis of type 1 or 2 diabetes for a minimum of 6 months duration as
             determined via medical record or source documentation by an individual qualified to
             make a medical diagnosis

          3. Adequate venous access as assessed by investigator or appropriate staff

        Exclusion Criteria:

          1. Subject will not tolerate tape adhesive in the area of Harmony 1 Sensor placement as
             assessed by qualified individual.

          2. Subject has any unresolved adverse skin condition in the area of Harmony 1 Sensor or
             device placement (e.g., psoriasis, rash, Staphylococcus infection)

          3. Subject is actively participating in an investigational study (drug or device)
             wherein they have received treatment from an investigational study (drug or device)
             in the last 2 weeks

          4. Subject is female and has a positive pregnancy screening test

          5. Females of child bearing age and who are sexually active should be excluded if they
             are not using a form of contraception deemed reliable by investigator

          6. Subject is female and plans to become pregnant during the course of the study

          7. Subject has had a hypoglycemic seizure within the past 6 months

          8. Subject has had hypoglycemia resulting in loss of consciousness within the past 6
             months prior to screening visit.

          9. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months
             prior to screening visit.

         10. Subject has a history of a seizure disorder

         11. Subject has central nervous system or cardiac disorder resulting in syncope

         12. Subject has a history of myocardial infarction, unstable angina, coronary artery
             bypass surgery, coronary artery stenting, transient ischemic attack (TIA),
             cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm
             disturbances or thromboembolic disease

         13. Subject has a hematocrit (Hct) lower than the normal reference range

         14. Subject has a history of adrenal insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Brazg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainer Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Christiansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diablo Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Smita Barua, M.A., M.P.A</last_name>
    <phone>(818) 576-5534</phone>
    <email>smita.barua@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Mottackel, M.S.</last_name>
    <phone>(818) 576-4886</phone>
    <email>robin.e.mottackel@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Christiansen, MD</last_name>
      <phone>925-930-7267</phone>
      <email>mchristiansen@diabloclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Margie Macarewich, RN</last_name>
      <phone>925-930-7267</phone>
      <email>mmacarewich@diabloclinical.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Brazg, MD</last_name>
      <phone>425-251-1720</phone>
      <email>rbrazg@rainier-research.com</email>
    </contact>
    <contact_backup>
      <last_name>Kristen Hughes</last_name>
      <phone>425-251-1720</phone>
      <email>khughes@rainier-research.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>December 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Harmony Sensor</keyword>
  <keyword>Continuous Glucose Monitoring</keyword>
  <keyword>CGM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
